Ascendia

  MARKET NEWS

Silo Pharma & Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application
4DMT Receives FDA Regenerative Medicine Advanced Therapy Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
Thermo Fisher Scientific’s PPD Clinical Research Business Selected by BARDA to Support Phase 2 Platform Clinical Trial to Treat ARDS
BriaCell Reports Unprecedented Preliminary Survival & Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset
ImmunoScape & MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification & Therapeutic Development

  FEATURED EDITORIAL

  COMPANY PROFILE

Cayman Chemical has been supplying high-purity lipids to the scientific community for more than 40 years. Our industry-leading expertise in lipid chemistry, synthesis, and purification is supported by state-of-the-art analytical equipment. We are committed to offering an unprecedented portfolio of lipid nanoparticle research toolsto support research and development. Our portfolio includes an impressive collection of ready-to-use and custom lipids for LNPs including ionizable cationic lipids, helper lipids, sterol lipids, and PEGylated lipids. We also offer research-ready LNPs to screen different LNP compositions and provide in-house lipid synthesis, screening, and LNP development services. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Sever Pharma Solutions Secures DEA License for Controlled Substances Handling in Putnam, CT

Sever Pharma Solutions Secures DEA License for Controlled Substances Handling in Putnam, CT

Sever Pharma Solutions recently announced the successful attainment of the Drug Enforcement Administration (DEA) license for its site in Putnam, CT. This license, effective as….

Abzena Partners With FDA on MAPPs Assay Publication

Abzena Partners With FDA on MAPPs Assay Publication

Abzena has recently co-authored a publication with the US FDA demonstrating the potential of the MHC Associated Peptide Proteomics (MAPPs) assay as an important method to interrogate immunogenicity risk….

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress & Key Milestones Accomplished

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress & Key Milestones Accomplished

Lipella Pharmaceuticals Inc. recently celebrated its first anniversary as a publicly traded entity. Based in Pittsburgh, PA, the company has made substantial strides over the past year, achieving critical milestones….

Successful Transfer of NDA Acknowledged by  FDA From Former Zosano Pharma to Emergex for Investigational Microneedle-Based Drug Delivery Patch

Successful Transfer of NDA Acknowledged by  FDA From Former Zosano Pharma to Emergex for Investigational Microneedle-Based Drug Delivery Patch

Emergex Vaccines Holding Limited recently announced the company has transferred ownership, as of May 2023, of the existing US FDA New Drug Application (NDA) of the investigational MAP originally intended….

  WHITEPAPERS & WEBINARS

WEBINAR - 2024 Trends in Topical Drug Delivery: Insights & Innovation

WEBINAR - 2024 Trends in Topical Drug Delivery: Insights & Innovation

This webinar will discuss some of the key trends from these leaders in the topical market on both a global and regional level, including the increased importance of sensory properties and the rise in non-conventional product formats, among others…..

WEBINAR - Enabling Upstream Intensified Bioprocessing

WEBINAR - Enabling Upstream Intensified Bioprocessing

Intensified upstream bioprocesses are being developed to increase productivity while reducing footprint, costs, and timelines for manufacturing. The higher cell densities generated by….

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Minimizing API Supply Chain Risks

WHITEPAPER - Minimizing API Supply Chain Risks

By the time your API is brought to a contract manufacturing organization (CMO), you have already put extensive amounts of resources into developing it. It becomes essential that you optimize your API supply chain to be aware of potential risks

…

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

Honeywell Aclar® thermoformable film enables pharmaceutical and medical device companies to achieve their sustainability commitments.

Aclar® film not only delivers a high moisture barrier to protect medicines, but it also reduces pack size, reduces waste, and reduces carbon emissions, compared

…

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

By: Dr. Bahar Yeniad and Dr. Pieter van Delft

Experts in copolymer microstructures have an important role to play in selecting biomaterials that can deliver desired performance of (bio)medical products. But how does microstructure link to the rate of API …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 10 – Excipients
January 17 – Drug Delivery